Lundbeck ups guidance, shifts jobs in restructure
This article was originally published in Scrip
Executive Summary
Lundbeck has upped its financial guidance for 2013 and given details of its rationalization program, which will hit 180-200 jobs as the firm restructures European business services and sets up a dedicated center in Poland. The company's 'Fit for the Future' program, which will run from 2013-2015, is expected to deliver an annual benefit of at least DKK500m ($90m) from 2016.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.